# Type I IFN receptor blockade by anifrolumab reduces cutaneous lupus in monogenic SLE

**Authors:** Julian Steininger, Christine Wolf, Min Ae Lee‐Kirsch, Claudia Günther

PMC · DOI: 10.1111/ddg.15806 · Journal Der Deutschen Dermatologischen Gesellschaft · 2025-06-26

## Full-text entities

- **Diseases:** cutaneous lupus (MESH:D008178), SLE (MESH:D008180)
- **Chemicals:** anifrolumab (MESH:C582345)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12548298/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12548298/full.md

## References

12 references — full list in the complete paper: https://tomesphere.com/paper/PMC12548298/full.md

---
Source: https://tomesphere.com/paper/PMC12548298